Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: LGC Clinical Diagnostics, Datar Cancer Genetics, OGT, More

LGC Clinical Diagnostics Seraseq Inherited Cancer DNA Mix v2

LGC Clinical Diagnostics has launched the Seraseq Inherited Cancer DNA Mix v2, a comprehensive reference material designed to support the validation and daily quality control of cancer predisposition assays. The product is designed to address the most challenging-to-detect mutations, ensuring that labs can confidently provide accurate, actionable insights for patients at risk of hereditary cancer syndromes. According to LGC, the new reference material includes 61 clinically relevant variants across 56 cancer-associated genes, about 2.5 times more targets than the previous version. These include rare and complex mutations such as the MSH2 Boland inversion and PMS2 pseudogene homologous variants.


Datar Cancer Genetics Target-MRD

Datar Cancer Genetics has launched Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. The test uses both tumor-agnostic next-generation sequencing and tumor-informed, patient-customized droplet digital PCR.


Oxford Gene Technology SureSeq Myeloid MRD Panel

Oxford Gene Technology has launched its new next-generation sequencing-based SureSeq Myeloid MRD Panel in North America. The test provides a flexible NGS workflow for the detection of ultra-low frequency biomarkers of measurable residual disease in acute myeloid leukemia. These include the largest and most complex AML-associated variants in key genes, such as large FLT3 internal tandem duplications, that often go undetected by previous generations of PCR-based enrichment technologies. OGT said its MRD panel targets 45 hotspot exons in 13 genes, with mean target coverage of up to 20,000X.


OnsiteGene XDive

OnsiteGene of San Diego has launched XDive, a real-time PCR instrument that completes 40 thermal cycles and real-time fluorescent imaging in five minutes. The company said XDive can process up to 16 samples per run with four optical channels and support up to 64 multiplexing targets. The platform is manufactured in an ISO13485-certified facility and has received US Food and Drug Administration Emergency Use Authorization for COVID-19 and monkeypox testing from both swab and saliva samples. The platform also uses a superfast master mix provided in a dried form for storage at room temperature that has a six-month shelf life. OnsiteGene said it is seeking global distributors, licensing opportunities, and collaboration partners for XDive.


The Health Alliance Bird Flu (Avian Influenza) Assay

The Health Alliance has launched its Bird Flu (Avian Influenza) Assay for the detection of infections in humans with H5N1 avian influenza virus. The firm said it developed the PCR-based assay through a collaboration with Thermo Fisher Scientific and validated it in one of Health Alliance's national labs.